



Incentive for Manufacturers of Pharmaceutical Products



- Manufacturers of pharmaceutical products, including vaccines, will be subject to the following tax rates, according to the Budget 2021:
 - for the first 10 years, 0% to 10%
 - for the next 10 years, 10%.
- On 17 February 2022, the Minister, in the exercise of the powers conferred by paragraph 154(1)(b) of, and subsection 6(1A) and paragraph 2 of Part XVII of Schedule 1 to, the Income Tax Act 1967 [Act 53], gazetted the Income Tax (The Incentive for Manufacturers of Pharmaceutical Products Scheme) Rules 2022 [P.U. (A) 34] to legislate the above incentives.
- These Rules have effect from the year of assessment 2021.

Incentive for Manufacturers of Pharmaceutical Products



- To be eligible for the incentive, the Minister must receive the application through submission to the Malaysian Investment Development Authority (MIDA) on or after 1 January 2021 but not later than 31 December 2022 and approved, according to the Rules.
- The activities listed in the rules are considered to be qualifying activities for such an incentive scheme.
- The Rules provide that the Minister may accept the surrender of the incentive by the qualifying company granted under these Rules at any time (except in the event that the qualifying company fails to comply with any conditions imposed) upon receipt of a written notice from the qualifying company to the Minister through MIDA.

Incentive for Manufacturers of Pharmaceutical Products




- Unless otherwise indicated in these Rules, a qualifying company approved under the Incentive for Manufacturers of Pharmaceutical Products Scheme must comply with all of the conditions specified as follows:
 - within one year of receiving the approval letter, the qualifying company must incur the first qualifying capital expenditure, excluding land.
 - a qualifying company must incur the entire amount of the qualifying capital expenditure as mentioned in the approval letter within five years of the date on which the first qualifying expenditure is incurred
 - any conditions in the Schedule (as defined in the Rules) and any other requirements imposed by the Minister as indicated in the approval letter and Guidelines for Incentive for Manufacturers of Pharmaceutical Products, including vaccines, under the 2021 Budget issued or revised by MIDA;

对医药产品制造商的奖掖措施



- 根据2021年预算案，包括疫苗在内的医药产品制造商将被征收以下税率:-
 - 首10年 - 0%至10%。
 - 之后10年 - 10%。
- 2022年2月17日，部长在行使《1967年所得税法令》[第53号法案]第154(1)(b)段和第6(1A)条文以及附表1第十七部分第2段所赋予的权力，在宪报上颁布了2022年所得税(医药产品制造商奖励计划)细则 [P.U. (A) 34]，以立法上述奖掖措施。
- 此细则从2021年的评估年开始生效。


对医药产品制造商的奖掖措施




- 根据细则，为了享有奖掖资格，部长必须在2021年1月1日或之后但不迟于2022年12月31日收到通过提交给马来西亚投资发展局 (MIDA) 的申请并获得批准。
- 细则中所列的活动被指定为此项奖掖计划的合格活动 [Qualifying Activities]。
- 细则也规定，除非合格公司未能遵守任何规定的条件外，部长在收到合格公司通过 MIDA 向部长发出的书面通知后，可在任何时候接受合格公司提出撤销根据本细则所授予的奖掖。


02/24/22 What's New 7

对医药产品制造商的奖掖措施




- 除非本细则中另有说明，在医药产品制造商奖掖计划下获得批准的合格公司必须遵守以下规定的所有条件：
 - 在收到批准书的一年内，合格的公司必须产生第一笔合格的资本支出 [qualifying capital expenditure]，但不包括土地。
 - 合格的公司必须在产生第一笔合格的资本支出之日起的五年内产生批准信中提到的全部合格的资本支出 [qualifying capital expenditure]
 - 细则附表中定义的任何条件，以及部长在批准信中规定的任何其他条件和 MIDA 发布或修订的2021年预算案对包括疫苗在内的医药产品制造商的奖掖指南中提出的任何其他要求。


02/24/22 What's New 8



➤ 免责声明 / Disclaimer



- 当你以我们的视频及刊物上的内容作为参考时，你需要：
 - ✓ 查询相关资料是否依然合时、准确和完整；和
 - ✓ 寻求本身独立的专业意见，因为各别案例所涉及的范围和层面皆不同。
- When you apply the content in our videos and publications as a reference, you need to:
 - ✓ check the information contained therein, whether it's up-to-date, accurate and complete, and
 - ✓ seek your independent professional advice because the scope and extent involved in each case are different.



9

Your Trusted Accountants



FEEL THE CCS & CO DIFFERENCE

CCS & Co provides clients with the specialized accounting support and services they need, allowing them to focus on their businesses and personal lives. We have been in the industry since 2004, and our team of professionals work diligently, in accordance with the highest professional standards.



| | |
|---------------|--|
| Address: | 38-1 Jalan Radin Anum, Bandar Baru Seri Petaling, 57000 Kuala Lumpur |
| Contact No | 03 – 9058 8313 |
| Email Address | info@ccs-co.com |



10

For further consultation, please contact:

Chin Chee Seng
Partner
+6012 365 4331
cschin@ccs-co.com

Wong Woei Teng
Audit Partner
+6017 237 8233
woeiteng@ccs-co.com

Jared Low
Assurance Director
+6018 763 4813
jared@ccs-co.com

CCS & Co

© 2022 CCS. All rights reserved. Not for further distribution without the permission of CCS & Co. "CCS" refers to the network of member firms of CCS & Co. The information contained in the slides represents the views of CCS and does not constitute the provision of professional advice of any kind. The information contained in the slides is based on our interpretation of existing legislation as of the published date. While CCS makes reasonable efforts to provide information which we believe to be reliable, we make no representations or warranties that the information provided is complete, accurate, up to date, or non-misleading. The information provided herein should not be used as a substitute for consultation with professional advisers. Before making any decision or taking any action, you should consult a professional adviser who has been provided with all the pertinent facts relevant to your particular situation. No responsibility for loss occasioned to any person acting or refraining from action as a result of using the information in the slides can be accepted by CCS.